Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Jeong, Jae Min; Knapp, F. F.

doi:10.1053/j.semnuclmed.2007.10.003

Cited by 49 publications

(15 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…188-Re is inexpensively produced from an on-site 188-W/188-Re generator (29,30). The generator is shipped to hospitals where its shelf-life is several months and the specific activity of the eluted 188-Re is > 25.9 mBq/mL (31).…”

Section: Discussionmentioning

confidence: 99%

The Somatostatin Analog ¹⁸⁸Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

et al. 2014

View full text Add to dashboard Cite

P2045 is a peptide analog of somatostatin with picomolar affinity for the somatostatin receptor subtype 2 (SSTR2) upregulated in some pancreatic tumors. Studies were conducted in rat AR42J pancreatic tumor-xenograft mice to determine if Re-188-P2045 could inhibit the growth of pancreatic cancer in an animal model. Methods Re-188-P2045 was intravenously administered every 3 days for 16 days to nude mice with AR42J tumor-xenografts that were ≈ 20 mm3 at study initiation. Tumor volumes were recorded throughout the dosing period. At necropsy all tissues were assessed for levels of radioactivity and evaluated for histological abnormalities. Clinical chemistry and hematology parameters were determined from terminal blood samples. The affinity of non-radioactive Re-185/187-P2045 for somatostatin receptors was compared in human NCI-H69 and rat AR42J tumor-cell membranes expressing predominantly SSTR2. Results In the 1.85 and 5.55 mBq groups tumor growth was inhibited in a dose-dependent fashion. In the 11.1 mBq group tumor growth was completely inhibited throughout the dosing period and for 12 days after the last administered dose. The radioactivity level in tumors 4 hours post-injection was 10%ID/g, which was 2-fold higher than in the kidneys. Re-188-P2045 was well tolerated in all dose-groups with no adverse clinical, histological, or hematological findings. The non-radioactive Re-185/187-P2045 bound more avidly (0.2 nM) to SSTR2 in human than rat tumor membranes suggesting that these studies are relevant to human studies. Conclusion Re-188-P2045 is a promising therapeutic candidate for patients with somatostatin-receptor-positive cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The Somatostatin Analog ¹⁸⁸Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Classical approaches include trans-arterial chemo-embolization (TACE) or IRT through administration of radionuclide-lipiodol complexes that have the advantage of being highly retained by hepatic tumours. [28][29][30][31][32][33][34][35] However, TACE is not suitable for advanced disease or patients with an obstructed (thrombotic) portal vein, whereas radiolabelled lipiodol (e.g.…”

Section: Discussionmentioning

confidence: 99%

Radiochemical and biological evaluation of novel ¹⁵³Sm/¹⁶⁶Ho‐amino acid–chitosan complexes

Marques

Gano

Batista

et al. 2008

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Ho complexes with the novel amino acid-chitosan polymers, N-(c-propanoylvalin)-chitosan (CHICO-val) and N-(c-propanoyl-aspartic acid)-chitosan (CHICO-asp). The main goal of this study was to obtain data on the radiochemical and biological behaviour of these complexes and information regarding their therapeutic potential when compared to 153 153 Sm complexes was studied in mice. The radioactive amino acid-chitosans can be directly injected into blood stream without significant retention on injection site, being trapped by liver. Biodistribution studies suggest that the radioactive amino acid-chitosans, due to its water solubility and stability may be considered potential candidates to be further explored for liver targeted nuclear therapy.

show abstract

“…A W-188/Re-188 generator similar to the prototype in the Oak Ridge National Laboratory (ORNL) [5] is based on the use of an aluminum oxide column permitting elution with normal saline. The use of this generator system in various institutions has demonstrated high yields of Re-188 accompanied with low W-188 parent breakthrough during periods of several months.…”

Section: The W-188/re-188 Generatormentioning

confidence: 99%

“…Re-188 DMSA shows selectivity for bone metastases and kidney, but uptake in normal bone is not significantly greater than in surrounding soft tissues [8]. Re-188 HDD (Lipiodol) (4-hexadecyl-1, 2, 9, 9-tetramethyl-4, 7-diaza-1,10-decanethiol) is also utilized for the treatment of hepatocellular carcinomas (HCC) [5]. The administration of the radiopharmaceutical is happening directly to the liver through a catheter which is inserted transfemorally and introduced into the proper hepatic artery [9].…”

Section: Clinical Applicationsmentioning

confidence: 99%

Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy

Argyrou

Valassi

Andreou

et al. 2013

International Journal of Molecular Imaging

View full text Add to dashboard Cite

Rhenium-188 (Re-188) is a high energy β-emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy γ-emission, which could be detected by γ-cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the β-emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.

show abstract

Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Cited by 49 publications

References 44 publications

The Somatostatin Analog ¹⁸⁸Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

The Somatostatin Analog ¹⁸⁸Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

Radiochemical and biological evaluation of novel ¹⁵³Sm/¹⁶⁶Ho‐amino acid–chitosan complexes

Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy

Contact Info

Product

Resources

About

Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Cited by 49 publications

References 44 publications

The Somatostatin Analog 188Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

The Somatostatin Analog 188Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

Radiochemical and biological evaluation of novel 153Sm/166Ho‐amino acid–chitosan complexes

Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy

Contact Info

Product

Resources

About

The Somatostatin Analog ¹⁸⁸Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

The Somatostatin Analog ¹⁸⁸Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

Radiochemical and biological evaluation of novel ¹⁵³Sm/¹⁶⁶Ho‐amino acid–chitosan complexes